GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » 3-Year FCF Growth Rate

CymaBay Therapeutics (CymaBay Therapeutics) 3-Year FCF Growth Rate : -1.90% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics 3-Year FCF Growth Rate?

CymaBay Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -1.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of CymaBay Therapeutics was 31.60% per year. The lowest was -18.40% per year. And the median was -1.90% per year.


Competitive Comparison of CymaBay Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, CymaBay Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CymaBay Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's 3-Year FCF Growth Rate falls into.



CymaBay Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


CymaBay Therapeutics  (NAS:CBAY) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


CymaBay Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103